Human GzmB(Granzyme B) ELISA Kit
中文名称：人颗粒酶B(GzmB)酶联免疫吸附测定试剂盒
Price:
- 反应性： Human
- 检测范围： 15.63-1000 pg/mL
- 灵敏度： 9.38 pg/mL
| 产品应用 | ELISA |
| 检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人GzmB抗体包被于酶标板上，实验时样品（或标准品）中的人GzmB会与包被抗体结合。后依次加入生物素化的抗人GzmB抗体和辣根过氧化物酶标记的亲和素，抗人GzmB抗体与结合在包被抗体上的人GzmB结合，生物素与亲和素特异性结合而形成免疫复合物，游离的成分被洗去。加入显色底物(TMB)，TMB在辣根过氧化物酶的催化下呈现蓝色，加终止液后变成黄色。用酶标仪在450 nm波长处测OD值，GzmB浓度与OD450值之间呈正比，通过绘制标准曲线计算出样品中GzmB的浓度。 |
| 反应类型 | Sandwich-ELISA |
| 规格 |
96 T
/ 48 T
/ 96 T × 5
|
| 反应时间 | 3 h 30 min |
| 反应性 | Human |
| 检测方法 | 比色法;ELISA;夹心法 |
| 检测范围 | 15.63-1000 pg/mL |
| 灵敏度 | 9.38 pg/mL |
| 样本体积 | 100 μL |
| 样本类型 | 血清、血浆或其他生物体液 |
| 特异性 | 可检测样本中的人GzmB，且与其它类似物无明显交叉反应 |
| 精密度 | 板内，板间变异系数均<10% |
| 回收率 | 80%-120% |
| 储存条件 | 2-8℃ |
| 有效期 | 12个月 |
| 数据处理 |
-
Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer
IF: 15.500 -
Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation
IF: 9.100 -
Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2
IF: 8.000 -
Helicobacter pylori infection induces POU5F1 upregulation and SPP1 activation to promote chemoresistance and T cell inactivation in gastric cancer cells
IF: 5.300Journal： BIOCHEMICAL PHARMACOLOGY (2024) -
Chrysin Enhances Anti-cancer Activity of Jurkat T Cell and NK-92 Cells Against Human Breast Cancer Cell Lines
IF: 2.300 -
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
IF: 28.500 -
Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour‐specific immunity
IF: 10.600Journal： Clinical and Translational Medicine (2023)PMID：37157934Reactivity：HumanSample Type：bladder tumour -
COPS6 promotes tumor progression and reduces CD8+ T cell infiltration by repressing IL-6 production to facilitate tumor immune evasion in breast cancer
IF: 8.200Journal： ACTA PHARMACOLOGICA SINICA (2023)PMID：37095198PMC10462724Reactivity：MouseSample Type：MCF-7 cell-xenograft -
IL-18 serves as a main effector of CAF-derived METTL3 against immunosuppression of NSCLC via driving NF-κB pathway
IF: 3.700 -
IL-2 Combined with IL-15 Enhanced the Expression of NKG2D Receptor on Patient Autologous NK Cells to Inhibit Wilms’ Tumor via MAPK Signaling Pathway
IF: 4.501Journal： Journal of Oncology (2022)PMID：36213822Reactivity：HumanSample Type：Wilms’ tumor (WT) tissue
实验操作视频
